Cytokinetics is now rapidly moving into commercialization efforts with Aficamten. Read more to see why I rate CYTK stock a ...

However, “pressure on shares seems overdone, given aficamten’s expected FDA approval and launch and several key upcoming data catalysts in 2025,” the analyst wrote, projecting over $3.6B in ...

Cytokinetics has a strong cash runway but faces risks from its Royalty Pharma deal. Read more on what's ahead for this ...

Cytokinetics (CYTK) on Monday shared new analyses related to aficamten’s effects associated with standard of care combination therapy and its ...

Cytokinetics (NASDAQ:CYTK) said EU regulators have validated the market application for its drug aficamten for the treatment ...

General and administrative expenses surged 41.3% to $62.3 million due to investments in the commercial readiness of lead pipeline candidate aficamten and personnel-related expenses. As of Dec. 31 ...

Cytokinetics has been steadily advancing aficamten through the regulatory process. The company submitted a New Drug Application (NDA) for aficamten in obstructive HCM (oHCM) in the third quarter of ...

New Analyses Related to Aficamten Expand on its Metabolism Pathways,Treatment Effect Associated with Combination Therapy with Disopyramideand ...

CYTK reports a wider-than-expected Q4 loss as operating expenses increase. CYTK is gearing up to launch lead candidate ...